Skip to main content
SpringerLink
Log in

Aprepitant cost effective when needed to control CINV

  • Clinical study
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Notes

  1. US dollars

Reference

  • Tsukiyama I, et al. Cost-utility analysis of aprepitant for patients who truly need it in a Japanese health care setting. 52nd Annual Meeting of the American Society of Clinical Oncology : abstr. e18243, 3 Jun 2016. Available from: URL: http://meetinglibrary.asco.org/content/163650-176

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Aprepitant cost effective when needed to control CINV. PharmacoEcon Outcomes News 758, 12 (2016). https://doi.org/10.1007/s40274-016-3241-8

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40274-016-3241-8

Search

Navigation